 Neoplasm Recurrence, Local
"Neoplasm Recurrence, Local" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The local recurrence of a neoplasm following treatment. It arises from microscopic cells of the original neoplasm that have escaped therapeutic intervention and later become clinically visible at the original site.
| Descriptor ID |
D009364
|
| MeSH Number(s) |
C04.697.655 C23.550.727.655
|
| Concept/Terms |
Neoplasm Recurrence, Local- Neoplasm Recurrence, Local
- Local Neoplasm Recurrences
- Locoregional Neoplasm Recurrence
- Recurrences, Local Neoplasm
- Neoplasm Recurrences, Local
- Recurrence, Local Neoplasm
- Recurrence, Locoregional Neoplasm
- Local Neoplasm Recurrence
- Neoplasm Recurrence, Locoregional
- Locoregional Neoplasm Recurrences
- Neoplasm Recurrences, Locoregional
- Recurrences, Locoregional Neoplasm
|
Below are MeSH descriptors whose meaning is more general than "Neoplasm Recurrence, Local".
Below are MeSH descriptors whose meaning is more specific than "Neoplasm Recurrence, Local".
This graph shows the total number of publications written about "Neoplasm Recurrence, Local" by people in this website by year, and whether "Neoplasm Recurrence, Local" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 1 | 6 | 7 | | 1996 | 1 | 2 | 3 | | 1997 | 1 | 5 | 6 | | 1998 | 0 | 4 | 4 | | 1999 | 4 | 4 | 8 | | 2000 | 3 | 7 | 10 | | 2001 | 2 | 5 | 7 | | 2002 | 3 | 4 | 7 | | 2003 | 2 | 1 | 3 | | 2004 | 2 | 4 | 6 | | 2005 | 5 | 9 | 14 | | 2006 | 3 | 11 | 14 | | 2007 | 5 | 4 | 9 | | 2008 | 8 | 4 | 12 | | 2009 | 11 | 14 | 25 | | 2010 | 13 | 14 | 27 | | 2011 | 12 | 11 | 23 | | 2012 | 13 | 5 | 18 | | 2013 | 12 | 16 | 28 | | 2014 | 31 | 4 | 35 | | 2015 | 11 | 8 | 19 | | 2016 | 13 | 9 | 22 | | 2017 | 24 | 11 | 35 | | 2018 | 23 | 7 | 30 | | 2019 | 28 | 12 | 40 | | 2020 | 21 | 29 | 50 | | 2021 | 16 | 32 | 48 | | 2022 | 6 | 34 | 40 | | 2023 | 0 | 45 | 45 | | 2024 | 17 | 19 | 36 | | 2025 | 12 | 1 | 13 |
To return to the timeline, click here.
Below are the most recent publications written about "Neoplasm Recurrence, Local" by people in Profiles.
-
Gonzalez Bosquet J, Polio A, George E, Tarhini AA, Cosgrove CM, Huang MS, Corr B, Leiser AL, Salhia B, Darcy K, Tarney CM, Dood RL, Dockery LE, Edge SB, Cavnar MJ, Landrum L, Rounbehler RJ, Churchman M, Wagner VM. Training, Validating, and Testing Machine Learning Prediction Models for Endometrial Cancer Recurrence. JCO Precis Oncol. 2025 May; 9:e2400859.
-
Green AL, Minard CG, Liu X, Safgren SL, Pinkney K, Harris L, Link G, DeSisto J, Voss S, Nelson MD, Reid JM, Fox E, Weigel BJ, Glade Bender J. Phase I Trial of Selinexor in Pediatric Recurrent/Refractory Solid and CNS Tumors (ADVL1414): A Children's Oncology Group Phase I Consortium Trial. Clin Cancer Res. 2025 May 01; 31(9):1587-1595.
-
Dela Cruz FS, Fox E, DuBois SG, Friedman GK, Croop JM, Kim A, Morgenstern DA, Balis FM, Macy ME, Pressey JG, Watt T, Krystal JI, Vo KT, Mody R, Laetsch TW, Weigel BJ, O'Hara K, He CS, Aluri J, Okpara CE, Glade Bender JL. A Phase 1/2 Study of Lenvatinib in Combination With Everolimus in Recurrent and Refractory Pediatric and Young Adult Solid Tumors. Pediatr Blood Cancer. 2025 Jul; 72(7):e31692.
-
Madan R, El Alam RH, Walker CM, Bang TJ, Bartel TB, Batra K, Brixey AG, Christensen JD, Cox CW, Gonzalez AV, Little BP, Lui NS, Maxfield H, Moore WH, Qin A, Shroff GS, Yasufuku K, Chung JH. ACR Appropriateness Criteria? Lung Cancer-Surveillance After Therapy. J Am Coll Radiol. 2025 May; 22(5S):S319-S342.
-
Karol SE, Khaw SL, Zwaan CM, Baruchel A, Bittencourt H, Cooper TM, Flotho C, Fraser C, Forlenza CJ, Goldsmith KC, Macy ME, Morgenstern DA, O'Brien MM, Petit A, Ziegler DS, Reinhardt D, Opferman JT, Rubnitz JE, Onishi M, Dunshee DR, Dunbar F, Vishwamitra D, Ross JA, Chen X, Unnebrink K, Kammerlander M, Salem AH, Palenski TL, Sunkersett G, Place AE. Venetoclax Alone or in Combination With Chemotherapy in Paediatric and Adolescent/Young Adult Patients With Relapsed/Refractory Acute Myeloid Leukaemia. Pediatr Blood Cancer. 2025 Jul; 72(7):e31714.
-
Cho BC, Johnson M, Bar J, Schaefer E, Yoh K, Zer A, Moskovitz M, Lee SH, Moreno V, de Miguel M, Okuma Y, Kim JH, Lee CH, Peguero J, Ansell P, Biesdorf C, Saab R, Freise KJ, Ramies D, Jeng EE, Camidge DR. A phase 1b study of cofetuzumab pelidotin monotherapy in patients with PTK7-expressing recurrent non-small cell lung cancer. Lung Cancer. 2025 Apr; 202:108492.
-
Haight PJ, Sanchez M, Thomas SM, Smitherman C, Cosgrove C, Bae-Jump V, Crafton S, Hacker K, Ko E, Krivak T, Lara O, Moore K, Mullen MM, Pothuri B, Thaker PH, Washington C, Arend R, Corr B, Duska L, Jackson A, Konecny GE, Wright J, Secord A, Backes F. Platinum-free interval and response to platinum retreatment or lenvatinib/pembrolizumab in patients with recurrent endometrial cancer: A real-world endometrial cancer molecularly targeted therapy consortium cohort study. Gynecol Oncol. 2025 Mar; 194:98-104.
-
DuBois SG, Ogawa C, Moreno L, Moss? YP, Fischer M, Ryan AL, Vo KT, De Wilde B, Rubio-San-Simon A, Macy ME, Howell L, Shusterman S, Corradini N, Luksch R, Aerts I, Foster JH, Weiss BD, Karthik CP, Yuen E, Avsar E, Park JR, Marachelian A. A phase 1 dose-escalation study of LY3295668 erbumine as monotherapy and in combination with topotecan and cyclophosphamide in children with relapsed/refractory neuroblastoma. Cancer. 2025 Feb 15; 131(4):e35751.
-
Wilky BA, Schwartz GK, Gordon MS, El-Khoueiry AB, Bullock AJ, Henick B, Agulnik M, Singh A, Mahadevan D, Stebbing J, Delepine C, Chand D, Avagyan M, Wu W, Johnson B, Grossman JE, O'Day S, Trent JC, Jones RL, Tsimberidou AM. Botensilimab (Fc-enhanced anti-cytotoxic lymphocyte-association protein-4 antibody) Plus Balstilimab (anti-PD-1 antibody) in Patients With Relapsed/Refractory Metastatic Sarcomas. J Clin Oncol. 2025 Apr 10; 43(11):1358-1368.
-
Kawashima J, Endo Y, Woldesenbet S, Khalil M, Akabane M, Cauchy F, Shen F, Maithel S, Popescu I, Kitago M, Weiss MJ, Martel G, Pulitano C, Aldrighetti L, Poultsides G, Ruzzente A, Bauer TW, Gleisner A, Marques H, Groot Koerkamp B, Endo I, Pawlik TM. "Biological R2" resection for intrahepatic cholangiocarcinoma: identification of patients at risk for poor oncologic outcomes after curative-intent resection. HPB (Oxford). 2025 May; 27(5):619-629.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|